Announcements Trials
Browse Landscape

Phase

Phase 2 21Phase 3 20Phase 2/3 7Phase 1/2 5Phase 1 4Phase 4 3Phase NA 2

Status

Completed 63Recruiting 26Terminated 22Withdrawn 17Unknown 11Active not recruiting 8Not yet recruiting 5

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 4Genitourinary 1

Conditions

Pancreatic Neoplasms 2Urinary Bladder Neoplasms 1Liver Neoplasms 1Colorectal Neoplasms 1

Interventions

Bevacizumab 14Injections 13Drug Therapy 10Gemcitabine 9toripalimab 8venetoclax 7Specimen Handling 7Magnetic Resonance Spectroscopy 7Cyclophosphamide 7Carboplatin 7pembrolizumab 6irinotecan sucrosofate 6Temozolomide 6HMPL-013 6tislelizumab 5sintilimab 5fludarabine 5N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 5Fluorouracil 5Etoposide 5Cisplatin 5Biopsy 5osimertinib 4lenvatinib 4Rituximab 4Radiotherapy 4Pemetrexed 4Paclitaxel 4Oxaliplatin 4Leucovorin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × Not yet recruiting × Fluorouracil × Clear all
NCT07579195 2026-05-14

Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial

University of Washington

Phase 1/2 Not yet recruiting
12 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT07391566 2026-02-06

LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation

Luye Pharma Group Ltd.

Phase 1/2 Not yet recruiting
99 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT06409637 2024-05-10

FOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver Transplantation

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 1/2 Not yet recruiting
62 enrolled
Gastrointestinal

Liver Neoplasms

NCT06370754 2024-04-17

FD-IMPACT

Fudan University

Phase 1/2 Not yet recruiting
117 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT06259058 2024-03-15

Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 1/2 Not yet recruiting
96 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡